...
首页> 外文期刊>Einstein (So Paulo) >II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies
【24h】

II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

机译:II关于在原发性免疫缺陷患者中使用人免疫球蛋白的巴西共识

获取原文
           

摘要

In the last few years, new primary immunodeficiencies and genetic defects have been described. Recently, immunoglobulin products with improved compositions and for subcutaneous use have become available in Brazil. In order to guide physicians on the use of human immunoglobulin to treat primary immunodeficiencies, based on a narrative literature review and their professional experience, the members of the Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology prepared an updated document of the 1 st Brazilian Consensus, published in 2010. The document presents new knowledge about the indications and efficacy of immunoglobulin therapy in primary immunodeficiencies, relevant production-related aspects, mode of use (routes of administration, pharmacokinetics, doses and intervals), adverse events (major, prevention, treatment and reporting), patient monitoring, presentations available and how to have access to this therapeutic resource in Brazil.
机译:在最近几年中,已经描述了新的原发性免疫缺陷和遗传缺陷。最近,在巴西已经获得了具有改进的成分并用于皮下使用的免疫球蛋白产品。为了指导医生使用人类免疫球蛋白治疗原发性免疫缺陷,根据叙述性文献综述和他们的专业经验,巴西过敏和免疫学会原发性免疫缺陷组的成员编写了第一版的更新文件。 《巴西共识》,于2010年出版。该文件介绍了有关免疫球蛋白治疗在原发性免疫缺陷中的适应症和功效,与生产相关的方面,使用方式(给药途径,药代动力学,剂量和间隔),不良事件(主要,预防,治疗和报告),患者监测,可用的演示文稿以及如何在巴西使用这种治疗资源。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号